Literature DB >> 16730337

A novel missense mutation in the transmembrane domain of neuregulin 1 is associated with schizophrenia.

Consuelo Walss-Bass1, Wei Liu, Debbie F Lew, Ramon Villegas, Patricia Montero, Albana Dassori, Robin J Leach, Laura Almasy, Michael Escamilla, Henriette Raventos.   

Abstract

BACKGROUND: Although genetic factors are known to play an important role in schizophrenia, the identification of genes involved in this disorder has remained elusive. The neuregulin 1 gene is among the few candidate genes to have been implicated in schizophrenia susceptibility in several populations. However, no causal mutations within this gene have been identified.
METHODS: In attempts to identify polymorphisms within the neuregulin 1 gene, we performed DNA sequencing using 12 subjects with a history of psychosis from the Central Valley of Costa Rica. DNA genotyping and association studies were then performed in an extended cohort of 142 affected individuals and their relatives from the same population.
RESULTS: We identified a novel missense mutation (Val to Leu) in exon 11, which codes for the transmembrane region of the neuregulin 1 protein. Association analysis by the Family Based Association Test (FBAT) revealed that this mutation is associated with psychosis (p = .0049) and schizophrenia (p = .0191) in this population.
CONCLUSIONS: We report the finding of a missense mutation in the neuregulin 1 gene associated with schizophrenia. Additional analyses of an independent sample as well as detailed functional studies should be performed to determine the relevance of this novel polymorphism to the pathophysiology of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16730337     DOI: 10.1016/j.biopsych.2006.03.017

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  43 in total

1.  Deficiency of Aph1B/C-gamma-secretase disturbs Nrg1 cleavage and sensorimotor gating that can be reversed with antipsychotic treatment.

Authors:  T Dejaegere; L Serneels; M K Schäfer; J Van Biervliet; K Horré; C Depboylu; D Alvarez-Fischer; A Herreman; M Willem; C Haass; G U Höglinger; R D'Hooge; B De Strooper
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-14       Impact factor: 11.205

2.  In vivo and in vitro genetic evidence of involvement of neuregulin 1 in immune system dysregulation.

Authors:  Ketan Marballi; Marlon P Quinones; Fabio Jimenez; Michael A Escamilla; Henriette Raventós; Maria Clara Soto-Bernardini; Seema S Ahuja; Consuelo Walss-Bass
Journal:  J Mol Med (Berl)       Date:  2010-07-13       Impact factor: 4.599

Review 3.  Developmental vulnerability of synapses and circuits associated with neuropsychiatric disorders.

Authors:  Peter Penzes; Andres Buonanno; Maria Passafaro; Carlo Sala; Robert A Sweet
Journal:  J Neurochem       Date:  2013-05-22       Impact factor: 5.372

Review 4.  Presenilin: RIP and beyond.

Authors:  Matthew R Hass; Chihiro Sato; Raphael Kopan; Guojun Zhao
Journal:  Semin Cell Dev Biol       Date:  2008-11-27       Impact factor: 7.727

5.  Physiological and behavioral effects of amphetamine in BACE1(-/-) mice.

Authors:  R Madelaine Paredes; E Piccart; E Navaira; D Cruz; M A Javors; W Koek; M J Beckstead; C Walss-Bass
Journal:  Genes Brain Behav       Date:  2015-05-21       Impact factor: 3.449

Review 6.  Postmortem brain: an underutilized substrate for studying severe mental illness.

Authors:  Robert E McCullumsmith; John H Hammond; Dan Shan; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-10-04       Impact factor: 7.853

Review 7.  Impact of neuregulin-1 on the pathophysiology of schizophrenia in human post-mortem studies.

Authors:  Andrea Schmitt; Eleni Parlapani; Oliver Gruber; Thomas Wobrock; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

8.  Proteolytic Processing of Neuregulin 1 Type III by Three Intramembrane-cleaving Proteases.

Authors:  Daniel Fleck; Matthias Voss; Ben Brankatschk; Camilla Giudici; Heike Hampel; Benjamin Schwenk; Dieter Edbauer; Akio Fukumori; Harald Steiner; Elisabeth Kremmer; Martina Haug-Kröper; Moritz J Rossner; Regina Fluhrer; Michael Willem; Christian Haass
Journal:  J Biol Chem       Date:  2015-11-16       Impact factor: 5.157

Review 9.  Neuregulin-ERBB signaling in the nervous system and neuropsychiatric diseases.

Authors:  Lin Mei; Klaus-Armin Nave
Journal:  Neuron       Date:  2014-07-02       Impact factor: 17.173

Review 10.  Role of cannabis and endocannabinoids in the genesis of schizophrenia.

Authors:  Emilio Fernandez-Espejo; Maria-Paz Viveros; Luis Núñez; Bart A Ellenbroek; Fernando Rodriguez de Fonseca
Journal:  Psychopharmacology (Berl)       Date:  2009-07-24       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.